Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate

Journal of the American Academy of Dermatology

Volumn 76, Issue 1, 2017, Pages 81-90

  Wu, Jashin J ^a   Guérin, Annie ^b   Sundaram, Murali ^c   Dea, Katherine ^b   Cloutier, Martin ^b   Mulani, Parvez ^c  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b ANALYSIS GROUP   (United States)

^c ABBVIE INC   (United States)

Author keywords

cardiovascular event risk; methotrexate; myocardial infarction; psoriasis; stroke; transient ischemic attack; tumor necrosis factor inhibitors; unstable angina

Indexed keywords

ADALIMUMAB; ANTIHYPERTENSIVE AGENT; CYCLOOXYGENASE 2 INHIBITOR; ETANERCEPT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; METHOTREXATE; STEROID; DERMATOLOGICAL AGENT; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PSORIASIS; RISK ASSESSMENT; RISK REDUCTION; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; YOUNG ADULT; ADOLESCENT; ANGINA, UNSTABLE; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; ISCHEMIC ATTACK, TRANSIENT; KAPLAN MEIER METHOD; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; PROTECTION; STROKE; TIME FACTOR;

ADALIMUMAB; ADOLESCENT; ADULT; AGED; ANGINA, UNSTABLE; CARDIOVASCULAR DISEASES; DERMATOLOGIC AGENTS; ETANERCEPT; FEMALE; HUMANS; INFLIXIMAB; ISCHEMIC ATTACK, TRANSIENT; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PROTECTIVE FACTORS; PSORIASIS; RISK ASSESSMENT; STROKE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84993965468     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.07.042     Document Type: Article

References (32)

1. 1 Colombo, G., Altomare, G., Peris, K., et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag 4:2 (2008), 559–568.
2. 2 Perk, J., De Backer, G., Gohlke, H., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts.). Eur Heart J 33:13 (2012), 1635–1701.
3. 3 Prodanovich, S., Kirsner, R.S., Kravetz, J.D., Ma, F., Martinez, L., Federman, D.G., Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 145:6 (2009), 700–703.
4. 4 Xu, T., Zhang, Y.-H., Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies. Br J Dermatol 167:6 (2012), 1345–1350.
5. 5 Gelfand, J.M., Neimann, A.L., Shin, D.B., Wang, X., Margolis, D.J., Troxel, A.B., Risk of myocardial infarction in patients with psoriasis. JAMA 296:14 (2006), 1735–1741.
6. 6 Ahlehoff, O., Psoriasis and cardiovascular disease: epidemiological studies. Dan Med Bull, 58(11), 2011.
7. 7 Richard, M.-A., Barnetche, T., Horreau, C., et al. Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion. J Eur Acad Dermatol Venereol 27:Suppl 3 (2013), 2–11.
8. 8 Ahlehoff, O., Skov, L., Gislason, G., et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 273:2 (2013), 197–204.
9. 9 Ahlehoff, O., Gislason, G.H., Jørgensen, C.H., et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J 33:16 (2012), 2054–2064.
10. 10 Pietrzak, A., Bartosińska, J., Chodorowska, G., Szepietowski, J.C., Paluszkiewicz, P., Schwartz, R.A., Cardiovascular aspects of psoriasis: an updated review. Int J Dermatol 52:2 (2013), 153–162.
11. 11 Kimball, A.B., Guerin, A., Latremouille-Viau, D., et al. Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med 123:4 (2010), 350–357.
12. 12 Koebnick, C., Black, M.H., Smith, N., et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr 159:4 (2011), 577–583.
13. 13 Wu, J.J., Choi, Y.M., Bebchuk, J.D., Risk of myocardial infarction in psoriasis patients: a retrospective cohort study. J Dermatolog Treat, 2014, 1–5.
14. 14 Ahlehoff, O., Skov, L., Gislason, G., et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol 29:6 (2015), 1128–1134.
15. 15 Samarasekera, E.J., Neilson, J.M., Warren, R.B., Parnham, J., Smith, C.H., Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 133:10 (2013), 2340–2346.
16. 16 Mehta, N.N., Yu, Y., Pinnelas, R., et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 124:8 (2011), 775.e1–775.e6.
17. 17 Abuabara, K., Azfar, R.S., Shin, D.B., Neimann, A.L., Troxel, A.B., Gelfand, J.M., Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br J Dermatol 163:3 (2010), 586–592.
18. 18 Armstrong, E.J., Harskamp, C.T., Armstrong, A.W., Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc, 2(2), 2013, e000062.
19. 19 Wang, Y., Gao, H., Loyd, C.M., et al. Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol 132:8 (2012), 2067–2075.
20. 20 Prodanovich, S., Prodanowich, S., Ma, F., et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52:2 (2005), 262–267.
21. 21 Micha, R., Imamura, F., Wyler von Ballmoos, M., et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 108 (2011), 1362–1370.
22. 22 Hugh, J., Van Voorhees, A.S., Nijhawan, R.I., et al. The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 70 (2014), 168–177.
23. 23 Marks, J.L., Edwards, C.J., Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity. Ther Adv Musculoskelet Dis 4:3 (2012), 149–157.
24. 24 Wu, J.J., Poon, K.-Y.T., Channual, J.C., Shen, A.Y.-J., Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 148:11 (2012), 1244–1250.
25. 25 Wu, J.J., Tumor necrosis factor inhibitors and myocardial infarction in psoriasis. JAMA 310:10 (2013), 1075–1076.
26. 26 Dixon, W.G., Watson, K.D., Lunt, M., Hyrich, K.L., Silman, A.J., Symmons, D.P.M., Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56:9 (2007), 2905–2912.
27. 27 Gottlieb, A., Korman, N.J., Gordon, K.B., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58:5 (2008), 851–864.
28. 28 Vena, G.A., Vestita, M., Cassano, N., Can early treatment with biologicals modify the natural history of comorbidities?. Dermatol Ther 23:2 (2010), 181–193.
29. 29 Westlake, S.L., Colebatch, A.N., Baird, J., et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 50:3 (2011), 518–531.
30. 30 Adamson, D.M., Chang, S., Hansen, L.G., Health research data for the real world: the MarketScan databases. 2008, Thompson Healthcare, Ann Arbor, MI, b28.
31. 31 Quan, H., Sundararajan, V., Halfon, P., et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:11 (2005), 1130–1139.
32. 32 Nurmohamed MTT, Bao Y, Signorovitch J, Mulani PM, Furst DE. Use of anti-TNF therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis. In: 2012 annual meeting of EULAR. Vol. 71. Berlin, Germany; 2012:Abstract OP0002.–Abstract OP0002.